- Home
- SNX vs SLRX Comparison
SNX vs SLRX Comparison
Compare SNX & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNX
- SLRX
- Stock Information
- Founded
- SNX 1980
- SLRX N/A
- Country
- SNX United States
- SLRX United States
- Employees
- SNX N/A
- SLRX N/A
- Industry
- SNX Retail: Computer Software & Peripheral Equipment
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SNX Technology
- SLRX Health Care
- Exchange
- SNX Nasdaq
- SLRX Nasdaq
- Market Cap
- SNX 11.2B
- SLRX 1.8M
- IPO Year
- SNX 2003
- SLRX N/A
- Fundamental
- Price
- SNX $143.20
- SLRX $0.65
- Analyst Decision
- SNX Strong Buy
- SLRX
- Analyst Count
- SNX 9
- SLRX 0
- Target Price
- SNX $145.33
- SLRX N/A
- AVG Volume (30 Days)
- SNX 1.1M
- SLRX 312.1K
- Earning Date
- SNX 06-24-2025
- SLRX 08-08-2025
- Dividend Yield
- SNX 1.24%
- SLRX N/A
- EPS Growth
- SNX 19.95
- SLRX N/A
- EPS
- SNX 8.55
- SLRX N/A
- Revenue
- SNX $60,007,297,000.00
- SLRX N/A
- Revenue This Year
- SNX $4.63
- SLRX N/A
- Revenue Next Year
- SNX $4.23
- SLRX N/A
- P/E Ratio
- SNX $16.65
- SLRX N/A
- Revenue Growth
- SNX 6.60
- SLRX N/A
- 52 Week Low
- SNX $92.23
- SLRX $0.45
- 52 Week High
- SNX $145.10
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- SNX 72.55
- SLRX 34.94
- Support Level
- SNX $140.06
- SLRX $0.60
- Resistance Level
- SNX $143.31
- SLRX $0.70
- Average True Range (ATR)
- SNX 2.48
- SLRX 0.09
- MACD
- SNX -0.17
- SLRX -0.03
- Stochastic Oscillator
- SNX 90.66
- SLRX 5.95
About SNX TD SYNNEX Corporation
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.